Biotron’s proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. The company has developed a library of over 350 compounds with potential activity against a range of viral diseases.

Currently Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1. Importantly BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1.

Biotron’s viroporin approach has also demonstrated early in vitro activity against virus such as Dengue & Zika, with early stage development continuing in a range of viruses.

Dr Michelle Miller Interview Nov 2013 - Video